市場調査レポート

商品コード

1701087

ドラベ症候群の市場規模、シェア、成長分析、発作タイプ別、診断別、重症度別、治療別、エンドユーザー別、流通チャネル別、地域別 - 産業予測 2025～2032年

Dravet Syndrome Market Size, Share, and Growth Analysis, By Type of seizures (Myoclonic Seizures, Atonic Seizures), By Diagnosis (MRI, ECG), By Severity, By Treatment, By End-Use, By Distribution Channel, By Region - Industry Forecast 2025-2032

出版日: 2025年04月02日
発行: SkyQuest
ページ情報: 英文 219 Pages
納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 774,224円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 905,696円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,037,168円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=146.08円

全表示
概要
目次

概要

サンプル依頼リストに入れる

ドラベ症候群市場規模は2023年に3億7,617万米ドルと評価され、2024年の4億1,153万米ドルから2032年には8億4,438万米ドルに成長し、予測期間（2025年～2032年）のCAGRは9.4％で成長する見通しです。

ドラベ症候群は、まれで慢性的なてんかんの一種であり、主に生後1年目の乳幼児に発症し、発熱が引き金となることが多いです。この重篤な神経疾患は発作を繰り返すため、管理およびケアに大きな課題をもたらします。ドラベが進行するにつれ、患者は様々な合併症に直面し、専門的な医療ケアと患者とその家族双方への継続的なサポートの必要性が浮き彫りになります。本疾患の複雑性と特異性から、的を絞った介入とリソースの重要性が強調され、市場では革新的な治療と包括的なケアソリューションに対する需要が高まっています。ドラベ症候群の治療法や支援システムを開発する企業は、この脆弱な患者集団のニーズに対応する重要な機会を有しています。

北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他欧州地域
アジア太平洋地域
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋地域
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
中東・アフリカ
- GCC諸国
- 南アフリカ
- その他中東・アフリカ

競合情報

上位5社の比較
主要企業の市場ポジショニング（2024年）
主な市場企業が採用した戦略
最近の市場動向
企業の市場シェア分析（2024年）
主要企業の企業プロファイル
- 企業の詳細
- 製品ポートフォリオ分析
- 企業のセグメント別シェア分析
- 収益の前年比比較（2022-2024年）

主要企業プロファイル

Stoke Therapeutics（USA）
Lundbeck A/S（Denmark）
Sanofi（France）
Biocodex S.A.（France）
Jazz Pharmaceuticals plc（Ireland）
Ovid Therapeutics Inc.（USA）
AbbVie Inc.（USA）
PTC Therapeutics Inc.（USA）
Epygenix Therapeutics Inc.（USA）
Marinus Pharmaceuticals Inc.（USA）
Neurocrine Biosciences Inc.（USA）
Aquestive Therapeutics Inc.（USA）
Eisai Co., Ltd.（Japan）
Tevard Biosciences GmbH（Germany）
Anavex Life Sciences Corp.（USA）
Supernus Pharmaceuticals Inc.（USA）
Xenon Pharmaceuticals Inc.（Canada）
Zydus Lifesciences Ltd.（India）
Sun Pharmaceutical Industries Ltd.（India）
Lupin Ltd.（India）

結論と提言

Product Code: SQMIG35A2815

Dravet Syndrome Market size was valued at USD 376.17 million in 2023 and is poised to grow from USD 411.53 million in 2024 to USD 844.38 million by 2032, growing at a CAGR of 9.4% during the forecast period (2025-2032).

Dravet syndrome, a rare and chronic form of epilepsy, primarily manifests in infants during their first year of life, often triggered by fevers. This severe neurological condition leads to recurrent seizures, creating significant challenges for management and care. As Dravet progresses, patients face various complications, highlighting the critical need for specialized medical attention and continuous support for both patients and their families. The complexity and uniqueness of this disorder underscore the importance of targeted interventions and resources, indicating a demand for innovative treatments and comprehensive care solutions in the market. Companies developing therapies and support systems for Dravet syndrome have a significant opportunity to address the needs of this vulnerable patient population.

Top-down and bottom-up approaches were used to estimate and validate the size of the Dravet Syndrome market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Dravet Syndrome Market Segments Analysis

Global Dravet Syndrome Market is segmented by Type of seizures, Diagnosis, Severity, Treatment, End-Use, Distribution Channel and region. Based on Type of seizures, the market is segmented into Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive seizures and Others. Based on Diagnosis, the market is segmented into MRI, ECG and SCN1A testing. Based on Severity, the market is segmented into Mild, Moderate and Severe. Based on Treatment, the market is segmented into Seizure, Medication, Clobazam, Stiripentol, Sodium Valproate, Ketogenic diet, Vagus Nerve stimulation and Others. Based on End-Use, the market is segmented into Pharma companies, Hospitals, Diagnostic, Laboratories, Academic and Research Institutes and Others. Based on Distribution Channel, the market is segmented into Direct Tender, Hospital pharmacy, Retail Pharmacy and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Dravet Syndrome Market

One of the key market drivers for the Global Dravet Syndrome Market is the increasing prevalence of the disorder, which is a severe form of epileptic encephalopathy typically diagnosed in childhood. As awareness of Dravet syndrome grows among healthcare professionals and the general public, there is a rising demand for effective treatment options. The development and approval of innovative therapies, particularly targeted pharmacological agents and advanced treatment modalities such as cannabidiol-based medications, are further propelling market growth. Additionally, ongoing research into the genetic and molecular mechanisms of Dravet syndrome is expected to yield novel therapeutic approaches, enhancing treatment outcomes and fostering market expansion.

Restraints in the Dravet Syndrome Market

The Dravet Syndrome market encounters several restraints that could hinder its anticipated revenue growth. One significant challenge is the persistent societal stigma surrounding epilepsy and related seizure disorders, which leads to discrimination and misinformation in various regions around the world. This stigma often discourages individuals from pursuing treatment, as they may fear the negative perceptions associated with their condition. As a result, the reluctance to seek necessary medical care could adversely impact the market, limiting access to crucial therapies and treatments for those affected by Dravet Syndrome. Addressing these societal barriers will be vital for market progress.

Market Trends of the Dravet Syndrome Market

The Dravet syndrome market is witnessing a significant upswing, driven by recent regulatory advancements that enhance treatment options for this challenging condition. Key approvals, such as those for Stiripentol (Diacomit) and Epidiolex, have notably improved symptom management, showcasing Milestones in therapeutic interventions. The landscape is poised for further growth with the anticipated approval of ZX008 (Fintepla) from Zogenix, reflecting an increasing focus on innovative therapies that address unmet medical needs in the Dravet syndrome community. This convergence of regulatory support and innovative drug development positions the market for rapid expansion, meeting the needs of patients and caregivers alike.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Dravet Syndrome Market Size by Type of seizures & CAGR (2025-2032)

Market Overview
Myoclonic Seizures
Atonic Seizures
Partial Seizures
Tonic-Clonic Seizures
Photosensitive seizures
Others

Global Dravet Syndrome Market Size by Diagnosis & CAGR (2025-2032)

Market Overview
MRI
ECG
SCN1A testing

Global Dravet Syndrome Market Size by Severity & CAGR (2025-2032)

Market Overview
Mild
Moderate
Severe

Global Dravet Syndrome Market Size by Treatment & CAGR (2025-2032)

Market Overview
Seizure
Medication
Clobazam
Stiripentol
Sodium Valproate
Ketogenic diet
Vagus Nerve stimulation
Others

Global Dravet Syndrome Market Size by End-Use & CAGR (2025-2032)

Market Overview
Pharma companies
Hospitals
Diagnostic
Laboratories
Academic and Research Institutes
Others

Global Dravet Syndrome Market Size by Distribution Channel & CAGR (2025-2032)

Market Overview
Direct Tender
Hospital pharmacy
Retail Pharmacy
Others

Global Dravet Syndrome Market Size & CAGR (2025-2032)

North America (Type of seizures, Diagnosis, Severity, Treatment, End-Use, Distribution Channel)
- US
- Canada
Europe (Type of seizures, Diagnosis, Severity, Treatment, End-Use, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Type of seizures, Diagnosis, Severity, Treatment, End-Use, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Type of seizures, Diagnosis, Severity, Treatment, End-Use, Distribution Channel)
- Brazil
- Rest of Latin America
Middle East & Africa (Type of seizures, Diagnosis, Severity, Treatment, End-Use, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

Stoke Therapeutics (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lundbeck A/S (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biocodex S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Jazz Pharmaceuticals plc (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ovid Therapeutics Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
PTC Therapeutics Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Epygenix Therapeutics Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Marinus Pharmaceuticals Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Neurocrine Biosciences Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aquestive Therapeutics Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eisai Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Tevard Biosciences GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Anavex Life Sciences Corp. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Supernus Pharmaceuticals Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Xenon Pharmaceuticals Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Zydus Lifesciences Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sun Pharmaceutical Industries Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lupin Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments

ドラベ症候群の市場規模、シェア、成長分析、発作タイプ別、診断別、重症度別、治療別、エンドユーザー別、流通チャネル別、地域別 - 産業予測 2025～2032年

Dravet Syndrome Market Size, Share, and Growth Analysis, By Type of seizures (Myoclonic Seizures, Atonic Seizures), By Diagnosis (MRI, ECG), By Severity, By Treatment, By End-Use, By Distribution Channel, By Region - Industry Forecast 2025-2032

目次

イントロダクション

調査手法

エグゼクティブサマリー

市場力学と見通し

主な市場の考察

ドラベ症候群市場規模：発作タイプ別& CAGR（2025-2032）

ドラベ症候群市場規模：診断別& CAGR（2025-2032）

ドラベ症候群市場規模：重症度別& CAGR（2025-2032）

ドラベ症候群市場規模：治療別& CAGR（2025-2032）

ドラベ症候群市場規模：エンドユーザー別& CAGR（2025-2032）

ドラベ症候群市場規模：流通チャネル別& CAGR（2025-2032）

ドラベ症候群市場規模：地域別& CAGR（2025-2032）